| Released | Contributor | Author | Title | Pages | Price |
| 9-Dec-2009 | Pechala's Reports | Lubomir Pechala | PHARMASSET INC (VRUS=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 8-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 7-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for VRUS | 13 |
$25 |
| 6-Dec-2009 | PriceTarget Research, Inc. |
N/A
| Pharmasset has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 5-Dec-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 17 new Laggards. | 57 |
$20 |
| 5-Dec-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: PHARMASSET INC | 5 |
$25 |
| 5-Dec-2009 | Standard & Poor's Quantitative Report |
N/A
| Pharmasset Inc | 6 |
$25 |
| 4-Dec-2009 | Pechala's Reports | Frantisek Pechala | PHARMASSET INC (VRUS=US) 12-months forecast | 1 |
$15 |
| 3-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AIS , APPA , CPRX , NLTX , NBY , PCYC , VRUS , DDD -- DRUGS | 3 |
$4 |
| 3-Dec-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: PHARMASSET -- VRUS | 1 |
$4 |
1.00% Nasdaq 0.00%
Research Reports
